Graves' disease following commencement of alemtuzumab therapy: Case report discussing clinical considerations and possible pathophysiology

Coles, 2012, Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, Lancet, 10.1016/S0140-6736(12)61768-1 Demko, 2008, FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia, Oncol, 10.1634/theoncologist.2007-0218 Tuohy, 2015, Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy, J Neurol Neurosurg Psychiatry, 10.1136/jnnp-2014-307721 Coles, 1999, Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis, Lancet, 10.1016/S0140-6736(99)02429-0 Daniels, 2014, Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis, J Clin Endocrinol Metab, 99, 80, 10.1210/jc.2013-2201 Bakshi, 2003, Fatigue associated with multiple sclerosis: diagnosis, impact and management, Mult Scler, 10.1191/1352458503ms904oa Tsuno, 2005, Sleep and depression, J Clin Psychiatr, 10.4088/JCP.v66n1008 Jones, 2014, Mode of action and clinical studies with alemtuzumab, Exp Neurol, 10.1016/j.expneurol.2014.04.018 Coles, 2006, The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy, J Neurol, 10.1007/s00415-005-0934-5 Fehérvari, 2004, CD4+ Tregs and immune control, J Clin Invest, 10.1172/JCI200423395 Jones, 2009, IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H), J Clin Invest, 10.1172/JCI37878 Liu, 2013, IL-21–Producing Th cells in immunity and autoimmunity, J Immunol, 10.4049/jimmunol.1301454 Lorenzi, 2008, Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes, Arthritis Rheum, 10.1002/art.23122 Weetman, 2009, Immune reconstitution syndrome and the thyroid, Best Pract Res Clin Endocrinol Metabol, 10.1016/j.beem.2009.07.003 Jubault, 2000, Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients, J Clin Endocrinol Metab